Neuraxis announces publication of prospective study showing ib-stim™ improves quality of life of adolescents with ibs

Carmel, ind., sept. 12, 2023 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today announced the publication of prospective study of the effect of auricular percutaneous electrical nerve field stimulation on quality of life in children with pain related disorders of gut-brain interaction, a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ib-stim™ in children with post-concussion symptoms, featured in the september 2023 frontiers in pain research.
NRXS Ratings Summary
NRXS Quant Ranking